


**Amendments to the Claims:**

The following listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A pyrimidone of the formula (I)



and ~~their or its~~ pharmaceutically acceptable ~~salts salt~~, wherein X represents oxygen, sulfur or NR, wherein R represents hydrogen, hydroxyl, acyl, alkyl, alkoxy, aryl, amino, hydroxylamino, alkylamino, arylamino, acylamino, alkoxyamino group; the rings represented by A and B are selected from aryl or heteroaryl; R<sup>1</sup> and R<sup>3</sup> may be same or different and independently represent hydrogen, SR<sup>7</sup>, S(O)<sub>p</sub>R<sup>8</sup>; R<sup>2</sup> and R<sup>4</sup> may be same or different and independently represent halogen, hydroxyl, nitro, cyano, azido, nitroso, amino, formyl, alkyl, haloalkyl, acyl, alkoxy, monoalkylamino, dialkylamino, acylamino, alkoxycarbonyl, SR<sup>7</sup>, S(O)<sub>p</sub>R<sup>8</sup>, alkoxyalkyl groups or carboxylic acids; R<sup>5</sup> and R<sup>6</sup> may be same or different and independently represent halogen, hydroxyl, nitro, cyano, azido, nitroso, amino, formyl, aralkyl, haloalkyl, acyl, alkoxy, aryloxy, aralkoxy, heteroaryl, heterocyclyl, monoalkylamino, dialkylamino, acylamino, alkoxycarbonyl, SR<sup>7</sup>, S(O)<sub>p</sub>R<sup>8</sup>, alkoxyalkyl groups or COR<sup>9</sup>; R<sup>7</sup> represents hydrogen, alkyl or aryl; R<sup>8</sup> represents halogen, alkyl, amino, acylamino, arylamino or aryl group; R<sup>9</sup> represents hydrogen, hydroxyl, amino, halogen, alkyl, alkoxy, aryloxy, monoalkylamino, dialkylamino, acylamino, arylamino, groups; m is an integer and is in the range of 1 to 4; n is an integer and is in the range of 1 to 4; p represents an integer of 1 or 2.

2. (Currently Amended) The pyrimidone of the formula (I) as claimed in claim 1, wherein the ring systems represented by A and B are selected from phenyl, naphthyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, piperidinyl, piperazinyl, pyridyl, thienyl, furyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyrimidinyl, benzopyranyl, benzofuranyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, benzopyrrolyl, benzoxadiazolyl, benzothiadiazolyl, quinolinyl, isoquinolinyl, benzothienyl, benzofuranyl or indolyl.

3. (Previously Presented) A pyrimidone selected from:

5-Cyano-2-(4-chlorophenyl)-4-(methylthio)-1-[4-(methylthio)phenyl]-6-oxo-1,6-dihydropyrimidine;

5-Cyano-2-(4-fluorophenyl)-4-(methylthio)-1-[4-(methylthio)phenyl]-6-oxo-1,6-dihydropyrimidine;

5-Cyano-2-phenyl-4-(methylthio)-1-[4-(methylthio)phenyl]-6-oxo-1,6-dihydropyrimidine ;

5-Cyano-2-(trifluoromethylphenyl)-4-(methylthio)-1-[4-(methylthio)phenyl]-6-oxo-1,6-dihydropyrimidine;

5-Cyano-2-[(4-methylthio)phenyl]-4-(methylthio)-1-[4-fluorophenyl]-6-oxo-1,6-dihydropyrimidine;

5-Cyano-1-(4-methylphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-1,6-dihydropyrimidine;

5-Cyano-2-[(4-methylsulphonyl)phenyl]-4-(methylthio)-1-[4-methylphenyl]-6-oxo-1,6-dihydropyrimidine;

5-Carboxy-2-[(4-methylthio)phenyl]-4-(methylthio)-1-[4-methylphenyl]-6-oxo-1,6-dihydropyrimidine;

5-Cyano-1-(4-isopropylphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-1,6-dihydropyrimidine;

5-Cyano-1-(3,4-dimethylphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-1,6-dihydropyrimidine;

5-Cyano-1-(4-isopropylphenyl)-2-[4-(methylsulfonyl)phenyl]-4-(methylthio)-6-oxo-1,6-dihydropyrimidine;

5-Cyano-1-(3,4-dimethylphenyl)-2-[4-(methylsulfonyl)phenyl]-4-(methylthio)-6-oxo-1,6-dihydropyrimidine;

5-Cyano-1-(3,4,5-trimethoxyphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-1,6-dihydropyrimidine;

5-Cyano-1-(4-ethylphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-1,6-dihydropyrimidine;

1-(4-Bromophenyl)-5-cyano-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-1,6-dihydropyrimidine;

5-Cyano-1-(4-methoxyphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-1,6-dihydropyrimidine;

5-Cyano-1-(4-fluorophenyl)-4-(methylthio)-2-phenyl-6-oxo-1,6-dihydropyrimidine;

1-(4-Chlorophenyl)-5-cyano-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-1,6-dihydropyrimidine;

5-Cyano-1-(2,4-dimethylphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-1,6-dihydropyrimidine;

5-Cyano-2-(4-methylphenyl)-4-(methylthio)-1-[4-(methylthio)phenyl]-6-oxo-1,6-dihydropyrimidine;

5-Cyano-1-(4-methoxyphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-1,6-dihydropyrimidine;

1-(4-tert-Butylphenyl)-5-cyano-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-1,6-dihydropyrimidine;

5-Cyano-1-(4-methylphenyl)-4-(methylthio)-6-oxo-2-phenyl-1,6-dihydropyrimidine;  
 1-(4-n-Butylphenyl)-5-cyano-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-1,6-dihydropyrimidine;  
 5-Cyano-1-(4-fluorophenyl)-4-(methylthio)-6-oxo-2-pyridin-4-yl-1,6-dihydropyrimidine;  
 5-Cyano-1-(4-fluorophenyl)-4-(methylthio)-6-oxo-2-pyridin-3-yl-1,6-dihydropyrimidine;  
 5-Cyano-4-(methylthio)-1-[4-(methylthio)phenyl]-6-oxo-2-pyridin-3-yl-1,6-dihydropyrimidine;  
 5-Cyano-4-(methylthio)-1-[4-(methylthio)phenyl]-6-oxo-2-pyridin-4-yl-1,6-dihydropyrimidine;  
 5-Cyano-1-(4-fluorophenyl)-4-(methylthio)-6-oxo-2-pyridin-2-yl-1,6-dihydropyrimidine;  
 5-Cyano-4-(methylthio)-1-[4-(methylthio)phenyl]-6-oxo-2-pyridin-2-yl-1,6-dihydropyrimidine;  
 5-Cyano-4-(methylthio)-1-(4-methoxyphenyl)-6-oxo-2-pyridin-2-yl-1,6-dihydropyrimidine;  
 5-Cyano-4-(methylthio)-1-(3,4-dimethylphenyl)-6-oxo-2-pyridin-2-yl-1,6-dihydropyrimidine;  
 5-Cyano-4-(methylthio)-1-(4-ethylphenyl)-6-oxo-2-pyridin-2-yl-1,6-dihydropyrimidine;  
 5-Cyano-4-(methylthio)-1-(4-methylphenyl)-6-oxo-2-pyridin-2-yl-1,6-dihydropyrimidine;  
 5-Cyano-4-(methylthio)-1-(4-ethoxyphenyl)-6-oxo-2-pyridin-4-yl-1,6-dihydropyrimidine;  
 5-Cyano-4-(methylthio)-1-(4-methylphenyl)-6-oxo-2-pyridin-4-yl-1,6-dihydropyrimidine;  
 5-Cyano-4-(methylthio)-1-(4-isopropylphenyl)-6-oxo-2-pyridin-4-yl-1,6-dihydropyrimidine;  
 5-Cyano-4-(methylthio)-1-(4-ethylphenyl)-6-oxo-2-pyridin-3-yl-1,6-dihydropyrimidine;  
 5-Cyano-4-(methylthio)-1-(3,4-dimethylphenyl)-6-oxo-2-pyridin-3-yl-1,6-dihydropyrimidine;  
 5-Cyano-4-(methylthio)-1-(4-methoxyphenyl)-6-oxo-2-pyridin-3-yl-1,6-dihydropyrimidine;  
 Ethyl 1-(4-methylphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-1,6-dihydropyrimidine-5-carboxylate;

Ethyl 1-(4-fluorophenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-1,6-dihydropyrimidine-5-carboxylate;

Ethyl 2-(4-fluorophenyl)-4-(methylthio)-1-[4-(methylthio)phenyl]-6-oxo-1,6-dihydropyrimidine-5-carboxylate;

5-Carboxamido-1-(4-methylphenyl)-4-(methylsulfonyl)-2-[4-(methylsulfonyl)phenyl]-6-oxo-1,6-dihydropyrimidine;

5-Carboxamido-1-(4-methylphenyl)-2-[4-(methylsulfonyl)phenyl]-6-oxo-4-piperazin-1-yl-1,6-dihydropyrimidine;

5-Carboxamido-4-(methylamino)-1-(4-methylphenyl)-2-[4-(methylsulfonyl)phenyl]-6-oxo-1,6-dihydropyrimidine;

5-Carboxamido-1-(4-methylphenyl)-2-[4-(methylsulfonyl)phenyl]-4-morpholin-4-yl-6-oxo-1,6-dihydropyrimidine;

5-Carboxamido-2-(4-fluorophenyl)-4-(methylsulfonyl)-1-[4-(methylsulfonyl)phenyl]-6-oxo-1,6-dihydropyrimidine;

5-Carboxamido-2-(4-fluorophenyl)-4-(methylamino)-1-[4-(methylsulfonyl)phenyl]-6-oxo-1,6-dihydropyrimidine;

5-Carboxamido-2-(4-fluorophenyl)-1-[4-(methylsulfonyl)phenyl]-4-morpholin-4-yl-6-oxo-1,6-dihydropyrimidine;

5-Carboxamido-1-(3,4-dimethylphenyl)-4-(methylsulfonyl)-2-[4-(methylsulfonyl)phenyl]-6-oxo-1,6-dihydropyrimidine;

5-Cyano-2-(4-fluorophenyl)-4-hydroxy-1-[4-(methylsulfonyl)phenyl]-6-oxo-1,6-dihydropyrimidine;

5-Cyano-1-(3,4-dimethylphenyl)-4-hydroxy-2-[4-(methylsulfonyl)phenyl]-6-oxo-1,6-dihydropyrimidine;

5-Cyano-4-(methylamino)-1-(4-methylphenyl)-2-[4-(methylthio)phenyl]-6-oxo-1,6-dihydropyrimidine;

5-Cyano-1-(3,4-dimethylphenyl)-4-(methylamino)-2-[4-(methylthio)phenyl]-6-oxo-1,6-dihydropyrimidine;

5-Cyano-2-(4-fluorophenyl)-4-(methylamino)-1-[4-(methylthio)phenyl]-6-oxo-1,6-dihydropyrimidine;

4-[5-Cyano-1-(3,4-dimethylphenyl)-4-(methylthio)-6-oxo-1,6-dihydropyrimidin-2-yl]benzenesulfonyl chloride;

4-[5-Cyano-2-(4-ethoxyphenyl)-4-(methylthio)-6-oxopyrimidin-1(6*H*)-yl]benzenesulfonyl chlorid;

4-[5-Cyano-1-(4-methylphenyl)-4-(methylthio)-6-oxo-1,6-dihydropyrimidin-2-yl]benzenesulfonamide;

*N*-({4-[5-Cyano-1-(4-methylphenyl)-4-(methylthio)-6-oxo-1,6-dihydropyrimidin-2-yl]phenyl} sulfonyl)acetamide;

*N*-({4-[5-Cyano-1-(3,4-dimethylphenyl)-4-(methylthio)-6-oxo-1,6-dihydropyrimidin-2-yl]phenyl} sulfonyl)acetamide;


*N*-({4-[5-Cyano-1-(4-methylphenyl)-4-(methylthio)-6-oxo-1,6-dihydropyrimidin-2-yl]phenyl} sulfonyl)-2,2,2-trifluoroacetamide;

*N*-({4-[5-Cyano-1-(3,4-dimethylphenyl)-4-(methylthio)-6-oxo-1,6-dihydropyrimidin-2-yl]phenyl} sulfonyl)-2,2,2-trifluoroacetamide;


*N*-({4-[5-Cyano-1-(4-methylphenyl)-4-(methylthio)-6-oxo-1,6-dihydropyrimidin-2-yl]phenyl} sulfonyl)benzamide and

*N*-({4-[5-Cyano-1-(3,4-dimethylphenyl)-4-(methylthio)-6-oxo-1,6-dihydropyrimidin-2-yl]phenyl} sulfonyl)benzamide.


4. (Currently Amended) A process for the preparation of a pyrimidone of the formula (I)



and ~~their~~ or its pharmaceutically acceptable ~~salts~~ salt, wherein X represents oxygen, sulfur or NR, wherein R represents hydrogen, hydroxyl, acyl, alkyl, alkoxy, aryl, amino, hydroxylamino, alkylamino, arylamino, acylamino, alkoxyamino group; the rings represented by A and B are selected from aryl or heteroaryl;  $R^1$  and  $R^3$  may be same or different and independently represent hydrogen,  $SR^7$ ,  $S(O)_pR^8$ ,  $R^2$  and  $R^4$  may be same or different and independently represent halogen, hydroxyl, nitro, cyano, azido, nitroso, amino, formyl, alkyl, haloalkyl, acyl, alkoxy, monoalkylamino, dialkylamino, acylamino, alkoxycarbonyl,  $SR^7$ ,  $S(O)_pR^8$ , alkoxyalkyl groups or carboxylic acids;  $R^5$  and  $R^6$  may be same or different and independently represent halogen, hydroxyl, nitro, cyano, azido, nitroso, amino, formyl, aralkyl, haloalkyl, acyl, alkoxy, aryloxy, aralkoxy, heteroaryl, heterocyclyl, monoalkylamino, dialkylamino, acylamino, alkoxycarbonyl,  $SR^7$ ,  $S(O)_pR^8$ , alkoxyalkyl groups or  $COR^9$ ;  $R^7$  represents hydrogen, alkyl or aryl;  $R^8$  represents halogen, alkyl, amino, acylamino, arylamino or aryl group;  $R^9$  represents hydrogen, hydroxyl, amino, halogen, alkyl, alkoxy, aryloxy, monoalkylamino, dialkylamino, acylamino, arylamino, groups; m is an integer and is in the range of 1 to 4; n is an integer and is in the range of 1 to 4; p represents an integer of 1 or 2; with a proviso that when  $R^1$  represents hydrogen  $R^2$  is not hydrogen, which comprises reacting a compound of the formula (Ia)




where R represent (C<sub>1</sub>-C<sub>3</sub>) alkyl group, X, R<sup>5</sup> and R<sup>6</sup> are as defined above, with a compound of the formula (Ib)



wherein all symbols are as defined above, to produce a compound of formula (I).


5. (Currently Amended) A process for the preparation of a pyrimidone of the formula (I)




and their or its pharmaceutically acceptable salts salt, wherein X represents oxygen, sulfur or NR, wherein R represents hydrogen, hydroxyl, acyl, alkyl, alkoxy, aryl, amino, hydroxylamino, alkylamino, arylamino, acylamino, alkoxyamino group; the rings represented



by A and B are selected from aryl or heteroaryl;  $R^1$  and  $R^3$  may be same or different and independently represent hydrogen,  $SR^7$ ,  $S(O)_pR^8$ ;  $R^2$  and  $R^4$  may be same or different and independently represent halogen, hydroxyl, nitro, cyano, azido, nitroso, amino, formyl, alkyl, haloalkyl, acyl, alkoxy, monoalkylamino, dialkylamino, acylamino, alkoxy carbonyl,  $SR^7$ ,  $S(O)_pR^8$ , alkoxyalkyl groups or carboxylic acids;  $R^5$  and  $R^6$  may be same or different and independently represent halogen, hydroxyl, nitro, cyano, azido, nitroso, amino, formyl, aralkyl, haloalkyl, acyl, alkoxy, aryloxy, aralkoxy, heteroaryl, heterocyclyl, monoalkylamino, dialkylamino, acylamino, alkoxy carbonyl,  $SR^7$ ,  $S(O)_pR^8$ , alkoxyalkyl groups or  $COR^9$ ;  $R^7$  represents hydrogen, alkyl or aryl;  $R^8$  represents halogen, alkyl, amino, acylamino, arylamino or aryl group;  $R^9$  represents hydrogen, hydroxyl, amino, halogen, alkyl, alkoxy, aryloxy, monoalkylamino, dialkylamino, acylamino, arylamino, groups; m is an integer and is in the range of 1 to 4; n is an integer and is in the range of 1 to 4; p represents an integer of 1 or 2; with a proviso that when  $R^1$  represents hydrogen  $R^2$  is not hydrogen, which comprises reacting a compound of the formula (Ic)




where R represent ( $C_1$ - $C_3$ ) alkyl group and all other symbols are as defined above, with a compound of the formula (Id)




wherein all symbols are as defined above, to produce a compound of formula (I).

6. (Currently Amended) A process for the conversion of the pyrimidone of the formula (I) as claimed in claim 1,




wherein any one of the groups  $R^1$  and  $R^3$  represent  $SR^7$ , wherein  $R^7$  represents alkyl or aryl and all other symbols are as defined in claim 1, to novel pyrimidones of the formula (I) wherein any one of the groups  $R^1$  and  $R^3$  represent  $S(O)_pR^8$ , where  $p$  represents 1 or 2 and  $R^8$  represents alkyl or aryl, and all other symbols are as defined above, using an oxidizing agent.

7. (Currently Amended) A process for the conversion of the pyrimidone of the formula (I) as claimed in claim 1,




wherein any one of the groups  $R^1$  and  $R^3$  represent  $S(O)_p R^8$ , where  $p$  is 1 or 2,  $R^8$  represents alkyl or aryl and all other symbols are as defined in claim 1, to novel pyrimidones of the formula (I) wherein any one of the groups  $R^1$  and  $R^3$  represent  $S(O)_p R^8$ , where  $p$  is 1 or 2,  $R^8$  represents amino group and all other symbols are as defined in claim 1.

8. (Previously Presented) A process for the conversion of the pyrimidone of the formula (I) as claimed in claim 1,




wherein either of the groups  $R^1$  or  $R^3$  represent  $S(O)_p R^8$ , wherein  $R^8$  represents amino group and  $p$  represents an integer of 1 or 2 and all other symbols are as defined in claim 1, which comprises reacting compound of formula (Ie)



wherein  $R^1$  or  $R^3$  represents hydrogen and all other symbols are as defined in claim 1, with chlorosulfonic acid and ammonia.

9.-13. (Canceled)

14. (Original) A pharmaceutical composition which comprises a compound of formula (I)



as defined in claim 1 and a pharmaceutically acceptable carrier, diluent, excipient or solvate.

15. (Original) A pharmaceutical composition as claimed in claim 14, in the form of a tablet, capsule, powder, syrup, aerosol, solution or suspension.

16. (Original) A pharmaceutical composition which comprises a compound as claimed in claim 3 and a pharmaceutically acceptable carrier, diluent, excipient or solvate.

17. (Original) A pharmaceutical composition as claimed in claim 16, in the form of a tablet, capsule, powder, syrup, aerosol, solution or suspension.

18. (Currently Amended) ~~Use of a compound of formula (I) as claimed in claim 1, for the prophylaxis or treatment. A method of treating a condition selected from the group consisting of rheumatoid arthritis; osteoporosis; multiple myeloma; uveitis; acute and chronic myelogenous leukemia; ischemic heart disease; atherosclerosis; lung cancer, breast cancer and central nervous system cancer; ischemic-induced cell damage; pancreatic  $\beta$ -cell destruction; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS); and psoriasis comprising administering the compound of formula (I) as claimed in claim 1 in a pharmaceutically effective amount to a subject afflicted with one or more of the foregoing conditions and in need of treatment; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; asthma; muscle degeneration; cachexia; type I and type II diabetes; bone resorption diseases; ischemia reperfusion injury; atherosclerosis; brain trauma; multiple sclerosis; cerebral malaria; sepsis; septic shock; toxic shock syndrome; fever, and myalgias due to infection. HIV 1, HIV 2, HIV 3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses (including HSV 1, HSV 2), and herpes zoster infection.~~

19. (Currently Amended) ~~Use of a compound as claimed in claim 3, for the prophylaxis or treatment. A method of treating a condition selected from the group consisting of rheumatoid arthritis; osteoporosis; multiple myeloma; uveitis; acute and chronic myelogenous leukemia; ischemic heart disease; atherosclerosis; lung cancer, breast cancer and central nervous system cancer; ischemic-induced cell damage; pancreatic  $\beta$ -cell destruction; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS); and psoriasis comprising administering the compound as claimed in claim 3 in a pharmaceutically effective amount to a subject afflicted with one or more of the foregoing conditions and in need of treatment; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; asthma; muscle degeneration; cachexia;~~

type I and type II diabetes; bone resorption diseases; ischemia reperfusion injury; atherosclerosis; brain trauma; multiple sclerosis; cerebral malaria; sepsis; septic shock; toxic shock syndrome; fever, and myalgias due to infection. HIV 1, HIV 2, HIV 3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses (including HSV 1, HSV 2), and herpes zoster infection.

20. (Currently Amended) Use of a composition as claimed in claim 14, for the prophylaxis or treatment A method of treating a condition selected from the group consisting of rheumatoid arthritis, Paget's disease, osteoporosis, multiple myeloma, uveitis, acute or chronic myelogenous leukemia, pancreatic  $\beta$ -cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), and psoriasis comprising administering the composition as claimed in claim 14 in a pharmaceutically effective amount to a subject afflicted with one or more of the foregoing conditions in need of treatment, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV 1, HIV 2, HIV 3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection.

21.-36. (Canceled)